Figure 6.
Kinetics of chronically activated iNKT cells. (A) Surface expression of HLA-II (top) and CD161 (bottom) measured on days 0, 3, and 10 after activation with 3 different stimuli (n = 12). (B) Expression frequency fold change of HLA-II (top) and CD161 (bottom) using reducing ratios of stimulation of iNKT cells with CD3/CD28 Dynabeads and 100 IU IL-2 for 3 days (n = 13). Data are normalized against a condition with no CD3/CD28 Dynabeads added. (C) Expression frequency fold change of HLA-II (top) and CD161 (bottom) with 1:10 CD3/CD28 Dynabeads:iNKT stimulation and increasing concentrations of IL-2 for 3 days. Data are normalized against a condition with no IL-2 added (n = 6). Means ± standard error of the mean (A-C). *P = .05-.01; ****P < .0001.

Kinetics of chronically activated iNKT cells. (A) Surface expression of HLA-II (top) and CD161 (bottom) measured on days 0, 3, and 10 after activation with 3 different stimuli (n = 12). (B) Expression frequency fold change of HLA-II (top) and CD161 (bottom) using reducing ratios of stimulation of iNKT cells with CD3/CD28 Dynabeads and 100 IU IL-2 for 3 days (n = 13). Data are normalized against a condition with no CD3/CD28 Dynabeads added. (C) Expression frequency fold change of HLA-II (top) and CD161 (bottom) with 1:10 CD3/CD28 Dynabeads:iNKT stimulation and increasing concentrations of IL-2 for 3 days. Data are normalized against a condition with no IL-2 added (n = 6). Means ± standard error of the mean (A-C). *P = .05-.01; ****P < .0001.

Close Modal

or Create an Account

Close Modal
Close Modal